BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1402 related articles for article (PubMed ID: 19387415)

  • 1. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of measuring soluble receptor activators of nuclear factor-kappaB ligand and osteoprotegerin in bone metabolism of elderly women.
    Chiba Y; Onouchi T; Ikeda T; Adachi J; Tamura Y; Horiuchi T
    Gerontology; 2009; 55(3):275-80. PubMed ID: 19158438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
    Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
    Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
    Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
    Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RANKL:osteoprotegerin ratio and bone mineral density in children with untreated juvenile dermatomyositis.
    Rouster-Stevens KA; Langman CB; Price HE; Seshadri R; Shore RM; Abbott K; Pachman LM
    Arthritis Rheum; 2007 Mar; 56(3):977-83. PubMed ID: 17328075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omentin-1, visfatin and adiponectin levels in relation to bone mineral density in Iranian postmenopausal women.
    Tohidi M; Akbarzadeh S; Larijani B; Kalantarhormozi M; Ostovar A; Assadi M; Vahdat K; Farrokhnia M; Sanjdideh Z; Amirinejad R; Nabipour I
    Bone; 2012 Nov; 51(5):876-81. PubMed ID: 22971441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between circulating osteoprotegerin levels and bone mineral metabolism in healthy women.
    Oh KW; Rhee EJ; Lee WY; Kim SW; Oh ES; Baek KH; Kang MI; Choi MG; Yoo HJ; Park SW
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):244-9. PubMed ID: 15272921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Receptor activator of NF(Kappa)B ligand/osteoprotegerin (RANKL/OPG) system and osteopontin (OPN) serum levels in a population of apulian postmenopausal women.
    D'Amore M; Fanelli M; D'Amore S; Fontana A; Minenna G
    Panminerva Med; 2006 Dec; 48(4):215-21. PubMed ID: 17215793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased formation of 8-iso-prostaglandin F(2alpha) is associated with altered bone metabolism and lower bone mass in hypercholesterolaemic subjects.
    Mangiafico RA; Malaponte G; Pennisi P; Li Volti G; Trovato G; Mangiafico M; Bevelacqua Y; Mazza F; Fiore CE
    J Intern Med; 2007 Jun; 261(6):587-96. PubMed ID: 17547714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women.
    Dai Y; Shen L
    Chin Med J (Engl); 2007 Nov; 120(22):2017-21. PubMed ID: 18067789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating amounts of osteoprotegerin and RANK ligand: genetic influence and relationship with BMD assessed in female twins.
    Abrahamsen B; Hjelmborg JV; Kostenuik P; Stilgren LS; Kyvik K; Adamu S; Brixen K; Langdahl BL
    Bone; 2005 Apr; 36(4):727-35. PubMed ID: 15781001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum osteoprotegerin and its ligand in cirrhotic patients referred for orthotopic liver transplantation: relationship with metabolic bone disease.
    Monegal A; Navasa M; Peris P; Alvarez L; Pons F; Rodés J; Guañabens N
    Liver Int; 2007 May; 27(4):492-7. PubMed ID: 17403189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cathepsin K predicts femoral neck bone mineral density change in nonosteoporotic peri- and early postmenopausal women.
    Prezelj J; Ostanek B; Logar DB; Marc J; Hawa G; Kocjan T
    Menopause; 2008; 15(2):369-73. PubMed ID: 17882010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
    Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
    Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of serum leptin with age, body weight, body mass index, and bone mineral density in healthy mainland Chinese women.
    Zhong N; Wu XP; Xu ZR; Wang AH; Luo XH; Cao XZ; Xie H; Shan PF; Liao EY
    Clin Chim Acta; 2005 Jan; 351(1-2):161-8. PubMed ID: 15563886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The circulating concentration and ratio of total and high molecular weight adiponectin in post-menopausal women with and without osteoporosis and its association with body mass index and biochemical markers of bone metabolism.
    Sodi R; Hazell MJ; Durham BH; Rees C; Ranganath LR; Fraser WD
    Clin Biochem; 2009 Sep; 42(13-14):1375-80. PubMed ID: 19523465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of osteoprotegerin gene polymorphism on bone mass in postmenopausal women].
    Cheng Q; Zhu HM; Miao YX; Zhu XY; Chen XP; Zhang XM
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):274-7. PubMed ID: 15059506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 71.